Tri Locum Partners LP Apellis Pharmaceuticals, Inc. Transaction History

Tri Locum Partners LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$46.59 - $66.96 $6.75 Million - $9.7 Million	-144,849 Reduced 65.28%	77,048 $5.08 Million
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $9.59 Million - $13.5 Million	221,897 New	221,897 $11.5 Million
Q1 2022 May 16, 2022	SELL	$35.46 - $54.12 $11.3 Million - $17.2 Million	-318,269 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$30.74 - $49.16 $9.78 Million - $15.6 Million	318,269 New	318,269 $15 Million
Q1 2021 May 17, 2021	SELL	$40.8 - $57.39 $4.95 Million - $6.97 Million	-121,409 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$30.79 - $57.2 $3.74 Million - $6.94 Million	121,409 New	121,409 $6.95 Million

302

112M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.19B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Tri Locum Partners LP, based on Form 13F filings with the SEC.

Stay updated on Tri Locum Partners LP with notifications on news.